🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

In patients with atrial fibrillation and moderate-to-high risk of stroke, abelacimab, a monoclonal antibody that inhibits activation of factor XI, led to fewer bleeding events than rivaroxaban. Read the full AZALEA–TIMI 71 trial results: nej.md/3PJcknN #AFib

The FXI inhibitor abelacimab substantially lowers bleeding compared with rivaroxaban in AF patients in the recently published AZALEA-TIMI 71 trial, out now in NEJM Robert Giugliano Sid M. Patel nejm.org/doi/full/10.10…

🚨The AZALEA-TIMI 71 Trial now in NEJM from TIMI Study Group nejm.org/doi/10.1056/NE… 🧵 below👇🏼

In this study of 473 patients, very low levels of LDL achieved via PCSK9 inhibitors was not associated with cognitive decline over a median of 5 years. Further studies are needed to assess the generalizability to adults at higher risk of dementia. eviden.cc/3P3AmcQ

There doesn’t appear to be a floor with LDL—💥 lower is better, even in the elderly. Check out our work in JACC Journals sciencedirect.com/science/articl…

Now out in Nature Medicine, we developed an Endothelial Cell PRS for CAD that: 1) Quantifies a currently immeasurable axis of CAD risk 2) Identifies individuals who are LDL-sensitive 3) Establishes which Pts will have greatest CV benefit from early & aggressive lipid lowering

Intensive LDL-C lowering with Evolocumab may lead to greater relative reduction in cardiovascular events in patients with autoimmune or inflammatory diseases. André Zimerman @bweber04 ana laura kunzler @rgiuglaino ahajournals.org/doi/full/10.11…

Thrilled to be a part of this study led by superstar 🌟André Zimerman in Circulation 👇! FOURIER analysis, PCSK9i in systemic inflammatory diseases (RA most common AID), and check out André Zimerman 🔥thread summarizing key points of the study. Robert Giugliano Ana Laura Kunzler

Coverage in NEJM Journal Watch of André Zimerman's analysis of #evolocumab in patients in FOURIER TIMI 59 with autoimmune or inflammatory disease. Robert Giugliano jwatch.org/na58726/2025/0…

Great to meet up w/ EAS YF at #EASCongress2025! Always inspiring to connect w/ colleagues 🌍, and honored to have Profs. Ridker & Hansson join our session — a real privilege to learn from them & share insights w/ this amazing community! #MyEAS2025 Borge G Nordestgaard Christoph Binder